Drugs / Bezafibrate
Bezafibrate
also known as
BZF · Bezafibrato · Bezagen xl · Bezalip · Bezalip-mono · Bezatol sr · BM 15.075 · Fibrazate xl · +3 more
Trials 19 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00506298 Background | Jul 2007 → Apr 2009 | type 2 diabetes mellitus | Zalicus | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02584504 Background | Nov 2015 → Apr 2017 | hyperlipoproteinemia | Sanofi | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02984982 Background | Nov 2016 → Jul 2018 | acute coronary syndrome, hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03649269 Comparator | Jan → Nov 2014 | hypertriglyceridemia | Ciprés Grupo Médico CGM SC | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bezafibrate | “An Open Label Long-Term Study to Evaluate the Safety and Tolerability of the Fixed-Dose Combination (FDC) of Obeticholic Acid (OCA) and Bezafibrate (BZF) tablet in Subjects...” NCT06488911 ↗22“Patients will receive a dosage of 400mg Bezafibrate every day during 28 weeks” NCT01527318 ↗ “Ezetimibe, Bezafibrate or Fenofibrate at stable dose as background therapy.” NCT02584504 ↗ “Bezafibrate 400 mg/day” NCT05213988 ↗ |
| Known as | Bezafibrato | ChEMBL registry synonym — accepted as the source's own label CHEMBL264374 ↗ |
| Known as | Bezagen xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL264374 ↗ |
| Known as | Bezalip | ChEMBL registry synonym — accepted as the source's own label CHEMBL264374 ↗ |
| Known as | Bezalip-mono | ChEMBL registry synonym — accepted as the source's own label CHEMBL264374 ↗ |
| Known as | Bezatol sr | ChEMBL registry synonym — accepted as the source's own label CHEMBL264374 ↗ |
| Known as | BM 15.075 | ChEMBL registry synonym — accepted as the source's own label CHEMBL264374 ↗ |
| Known as | BZF | “An Open Label Long-Term Study to Evaluate the Safety and Tolerability of the Fixed-Dose Combination (FDC) of Obeticholic Acid (OCA) and Bezafibrate (BZF) tablet in Subjects...” NCT06488911 ↗2“investigational drug obeticholic acid (OCA) in combination with the investigational drug bezafibrate (BZF)” NCT04594694 ↗ “Two tablets of bezafibrate 200 mg IR once daily for BZF 400 mg IR” NCT05239468 ↗ |
| Known as | Fibrazate xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL264374 ↗ |
| Known as | Liparol xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL264374 ↗ |
| Known as | NSC-758174 | ChEMBL registry synonym — accepted as the source's own label CHEMBL264374 ↗ |
| Known as | Zimbacol xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL264374 ↗ |
| Action | Activate | “We recently shown that bezafibrate, a PPAR alpha agonist, was able to restore close to the normal the apparent CPT2 activity and the LCFAO in both fibroblasts and cultured...” NCT00336167 ↗ |
| Modality | Small molecule | “the hypolipidemic drug bezafibrate” NCT00983788 ↗ |
| Route | Oral | “Route of administration: oral” NCT02984982 ↗ |